A phase II study of low-dose erlotinib in frail patients with EGFR-mutant non-small cell lung cancer: TORG1425

Authors :: Hiroshi Tanaka
Kei Kusaka
Akihiro Bessho
Shingo Miyamoto
Kazuhiko Yamada
Tsuneo Shimokawa
Shinobu Hosokawa
Hideo Kunitoh
Yukio Hosomi
Koichi Azuma
Hiroaki Okamoto
Hiromi Aono
Yoshiro Nakahara
Hidenobu Ishii
Source :: Annals of Oncology. 29:vii59
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Mutant
Low dose
Phases of clinical research
Hematology
medicine.disease
Internal medicine
medicine
Frail elderly
Erlotinib
Non small cell
Lung cancer
business
medicine.drug

Full Text Access

Tools